These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28535400)

  • 21. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.
    Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Woodward L
    J Fam Pract; 1998 Feb; 46(2):136-41. PubMed ID: 9487319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deceiving high-grade cervical dysplasias identified as human papillomavirus non-16 and non-18 types by Invader human papillomavirus assays.
    Kitahara S; Chan RC; Nichols WS; Silva EG
    Ann Diagn Pathol; 2012 Apr; 16(2):100-6. PubMed ID: 22197542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Cervista HPV HR assay for detection of human papillomavirus in samples with hybrid capture borderline negative results.
    Galan-Sanchez F; Rodriguez-Iglesias MA
    APMIS; 2010 Sep; 118(9):681-4. PubMed ID: 20718720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.
    Tao K; Yang J; Yang H; Guo ZH; Hu YM; Tan ZY; Zhang F; Duan JL
    Diagn Cytopathol; 2014 Mar; 42(3):213-7. PubMed ID: 23904341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia.
    Kaufman RH; Adam E; Icenogle J; Lawson H; Lee N; Reeves KO; Irwin J; Simon T; Press M; Uhler R; Entman C; Reeves WC
    Am J Obstet Gynecol; 1997 Jan; 176(1 Pt 1):87-92. PubMed ID: 9024095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology.
    Kurian EM; Caporelli ML; Baker S; Woda B; Cosar EF; Hutchinson L
    Am J Clin Pathol; 2011 Nov; 136(5):808-16. PubMed ID: 22031321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.
    Iwata T; Hasegawa T; Ochiai K; Takizawa K; Umezawa S; Kuramoto H; Ohmura M; Kubushiro K; Arai H; Sakamoto M; Motoyama T; Watanabe K; Aoki D
    Reprod Sci; 2015 Dec; 22(12):1509-15. PubMed ID: 26092278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
    Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical squamous cells of undetermined significance in liquid-based cytologic specimens: results of reflex human papillomavirus testing and histologic follow-up in routine practice with comparison of interpretive and probabilistic reporting methods.
    Levi AW; Kelly DP; Rosenthal DL; Ronnett BM
    Cancer; 2003 Aug; 99(4):191-7. PubMed ID: 12925979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reflex human papilloma virus infection testing detects the same proportion of cervical intraepithelial neoplasia grade 2-3 in young versus elderly women.
    Eltoum IA; Chhieng DC; Roberson J; McMillon D; Partridge EE
    Cancer; 2005 Aug; 105(4):194-8. PubMed ID: 15900575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of HPV DNA cotesting in Korean women with ASCUS or ASC-H.
    Lee S; Kim JW; Hong JH; Song JY; Lee JK; Kim IS; Lee NW
    Diagn Cytopathol; 2014 Dec; 42(12):1058-62. PubMed ID: 24825374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age.
    Lin CT; Tseng CJ; Lai CH; Hsueh S; Huang HJ; Law KS
    J Reprod Med; 2000 Apr; 45(4):345-50. PubMed ID: 10804494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.